What the study found: Olutasidenib, an inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), was well tolerated in patients with recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma. In the conventional chondrosarcoma subgroup, the study reported disease control.
Why the authors say this matters: The authors conclude that chondrosarcoma has limited treatment options and that their findings indicate olutasidenib may have activity in conventional chondrosarcoma.
What the researchers tested: This was a phase 1b/2 clinical trial (NCT03684811) in patients with locally advanced or metastatic mIDH1 chondrosarcoma. Patients received olutasidenib 150 mg twice daily, and the study assessed objective response rate, adverse events, progression-free survival, and overall survival.
What worked and what didn't: Twenty-three patients were enrolled, including 16 with conventional chondrosarcoma. Among 21 response-evaluable patients, 11 had stable disease, 8 had progressive disease, and 2 were not evaluable. Median progression-free survival was 2.0 months overall and 3.5 months in conventional chondrosarcoma; median overall survival was 16.0 months overall and 19.0 months in conventional chondrosarcoma. No dose-limiting toxicities were reported.
What to keep in mind: The abstract notes an open-label design and a low patient sample because conventional chondrosarcoma is rare. It also does not report an objective response rate in the provided summary.
Key points
- Olutasidenib was studied in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma.
- The trial enrolled 23 patients, including 16 with conventional chondrosarcoma.
- Among response-evaluable patients, stable disease was more common than progressive disease.
- Median progression-free survival was 2.0 months overall and 3.5 months in conventional chondrosarcoma.
- No dose-limiting toxicities were reported.
- The study was open-label and had a small sample size.
Disclosure
- Research title:
- Olutasidenib showed disease control in IDH1-mutated chondrosarcoma
- Authors:
- Robin L. Jones, Roman Groisberg, Jean-Yves Blay, H. Colman, M. De La Fuente, Patricia Roxburgh, Mwe Mwe Chao, Hua Tian, Florence Duffaud, Rastislav Bahleda, Brian A. Van Tine
- Institutions:
- Royal Marsden Hospital, Rutgers, The State University of New Jersey, Rutgers Cancer Institute, Centre Léon Bérard, University of Utah, Huntsman Cancer Institute, University of Miami, Sylvester Comprehensive Cancer Center, University of Glasgow, Rigel (United States), Aix-Marseille Université, Institut Gustave Roussy, Washington University in St. Louis
- Publication date:
- 2026-01-29
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with peer-reviewed research without reading academic papers — one filtered digest, every Friday.